This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-10 and is reviewed periodically as new material appears.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
Moisture management and humidity control requires operating HVAC systems as designed. Moisture management and humidity control may conflict with efforts to conserve energy. For example, moisture management and humidity control requires systems to be set to supply make-up air at lower temperatures (design levels), instead of the higher temperatures sometimes used to conserve energy in cooling-dominated climate conditions. However, for most of the US and many parts of Europe and Japan, during the majority of hours of the year, outdoor air temperatures are cool enough that the air does not need further cooling to provide thermal comfort indoors. However, high humidity outdoors creates the need for careful attention to humidity levels indoors. High humidity give rise to mold growth and moisture indoors is associated with a higher prevalence of occupant respiratory problems. The "dew point temperature" is an absolute measure of the moisture in air. Some facilities are being designed with dew points in the lower 50s °F, and some in the upper and lower 40s °F. Some facilities are being designed using desiccant wheels with gas-fired heaters to dry out the wheel enough to get the required dew points. On those systems, after the moisture is removed from the make-up air, a cooling coil is used to lower the temperature to the desired level. Commercial buildings, and sometimes residential, are often kept under slightly positive air pressure relative to the outdoors to reduce infiltration. Limiting infiltration helps with moisture management and humidity control.
=== Hemolytic crisis === A hemolytic crisis, or hyperhemolytic crisis, is characterized by an accelerated rate of red blood cell destruction leading to anemia, jaundice, and reticulocytosis. Hemolytic crises are a major concern with sickle-cell disease and G6PD deficiency.
Alongside the general election, voters were asked to participate in a referendum regarding a proposed rewrite of the country's 2017 Constitution. On election night, unofficial results reported by Al Jazeera indicated that more than 57 per cent of voters had supported the drafting of a new constitution. People's Party leader Natthaphong Ruengpanyawut acknowledged that the referendum appeared to have been approved and stated his party would respect the parliamentary process. The proposal was carried. According to the Election Commission, 21,621,638 voters (60.16 per cent) approved the drafting of a new constitution, 11,241,653 (31.28 per cent) rejected it and 3,074,330 (8.55 per cent) expressed no opinion, from 35,937,621 valid ballots. A further 932,583 ballots were rejected as invalid. Turnout in the referendum was 36,870,266, or 69.65 per cent, about 937,000 fewer ballots than were cast in the general election held the same day. Support was broadly spread, with 288 of the 400 constituencies recording a 'yes' vote above 70 per cent and only 38 recording a 'no' vote above 50 per cent, two of them in Buriram and the remaining 36 in the upper south.
Sources: en.wikipedia.org
=== Pharmacodynamics === Nicotine acts as a receptor agonist at most nicotinic acetylcholine receptors (nAChRs), except at two nicotinic receptor subunits (nAChRα9 and nAChRα10) where it acts as a receptor antagonist. Such antagonism results in mild analgesia. The stereochemistry of nicotine is crucial to its biological effects. Due to the chiral nature of its receptors in the body, the (S)-enantiomer is substantially more active. For this reason, nearly all pharmacological and toxicological data is based on studies of (S)-nicotine. (S)-Nicotine is 4–28 times more potent than (R)-nicotine in standard nicotinic receptor binding and functional assays and elicits stronger nasal irritation, stinging, and mucosal responses at lower detection thresholds—yet smokers rated it as more pleasant in the only human sensory study. The pharmacological, metabolic, and toxicological effects of (R)-nicotine and of racemic (R)/(S)-nicotine mixtures in humans remain poorly understood, with data largely limited to animal studies.
== Clinical trials == The drug is currently under development by AbbVie. Navitoclax is used as mono-therapy as well as in combination with chemotherapies (paclitaxel, docetaxel, gemcitabine, and irinotecan), olaparib, erlotinib, venetoclax, and rituximab in advanced hematological malignancies (in both pediatric and adult patients) and solid tumors including ovarian cancer, breast cancer, lung cancer. Additionally, an ongoing global multi-center, randomized, open-label, phase 3 study evaluating efficacy and safety of navitoclax in combination with ruxolitinib versus best available therapy in adult patients with relapsed/refractory myelofibrosis was initiated on 31 August 2020. The study is expected to conclude in 2026.
==== Iodine ==== Iodine used for water purification is commonly added to water as a solution, in crystallized form, or in tablets containing tetraglycine hydroperiodide that release 8 mg of iodine per tablet. The iodine kills many, but not all, of the most common pathogens present in natural fresh water sources. Carrying iodine for water purification is an imperfect but lightweight solution for those in need of field purification of drinking water. Kits are available in camping stores that include an iodine pill and a second pill (vitamin C or ascorbic acid) that will remove the iodine taste from the water after it has been disinfected. The addition of vitamin C, in the form of a pill or in flavored drink powders, precipitates much of the iodine out of the solution, so it should not be added until the iodine has had sufficient time to work. This time is 30 minutes in relatively clear, warm water, but is considerably longer if the water is turbid or cold. If the iodine has precipitated out of the solution, then the drinking water has less available iodine in the solution. Tetraglycine hydroperiodide maintains its effectiveness indefinitely before the container is opened; although some manufacturers suggest not using the tablets more than three months after the container has initially been opened, the shelf life is in fact very long provided that the container is resealed immediately after each time it is opened. Similarly to potassium iodide (KI), sufficient consumption of tetraglycine hydroperiodide tablets may protect the thyroid against uptake of radioactive iodine.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.